Cytologic features of well differentiated G3 pancreatic neuroendocrine tumors

被引：0
|
作者：
Sigel, Carlie S. [1 ]
Silva, Vitor Werneck Krauss [1 ]
Reid, Michelle [2 ]
Chhieng, David [3 ]
Sigel, Keith [4 ]
Basturk, Olca [5 ]
Daniel, Tanisha [6 ]
Klimstra, David [7 ]
Tang, Laura [8 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[3] Univ Washington, Seattle, WA 98195 USA
[4] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[5] MSKCC, New York, NY USA
[6] Univ Med & Dent New Jersey, New Brunswick, NJ USA
[7] Mem Sloan Kettering, New York, NY USA
[8] Mem Sloan Kettering CC, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
485
引用
收藏
页码：175 / 175
页数：1
相关论文
共 50 条
  • [21] Sunitinib In Advanced, Well Differentiated Pancreatic Neuroendocrine Tumors
    Deeks, Emma D.
    Raymond, Eric
    BIODRUGS, 2011, 25 (05) : 307 - 316
  • [22] Claudin Expression in Well Differentiated Pancreatic Neuroendocrine Tumors
    Meunier, Rashna
    Mangray, Shamal
    Zhao, Chaohui
    Lombardo, Kara
    Noble, Lelia
    Lu, Shaolei
    Resnick, Murray
    Yakirevich, Evgeny
    MODERN PATHOLOGY, 2015, 28 : 446A - 446A
  • [23] Efficacy of Somatostatin Analog (SSA) Monotherapy for Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (NETs)
    McGarrah, P.
    Liu, A.
    Hobday, T.
    Starr, J.
    Kendi, A.
    Graham, R.
    Halfdanarson, T. R.
    Sonbol, M. B.
    PANCREAS, 2021, 50 (03) : 451 - 451
  • [24] Efficacy of somatostatin analog (SSA) monotherapy for well-differentiated grade 3 (G3) gastroenteropancreatic neuroendocrine tumors (NETs)
    McGarrah, Patrick Walsh
    Hobday, Timothy J.
    Starr, Jason Scott
    Kendi, Ayse T.
    Graham, Rondell P.
    Sonbol, Mohamad Bassam
    Halfdanarson, Thorvardur Ragnar
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [25] Well-Differentiated G1/G2 Pancreatic NETs Can Evolve Towards G3 Tumors
    Hentic, O.
    Cros, J.
    Rebours, V
    Zappa, M.
    Muller, N.
    Maire, F.
    Levy, P.
    Hammel, P.
    Couvelard, A.
    Levy, P.
    NEUROENDOCRINOLOGY, 2017, 105 : 135 - 135
  • [26] Expression of FOXM1 in G3 Neuroendocrine Tumors (NET G3) and G3 Neuroendocrine Carcinomas (NEC G3) of the Pancreas and the Intestine
    Briest, F.
    Konukiewitz, B.
    Anlauf, M.
    Kloppel, G.
    Grabowski, P.
    Sipos, B.
    NEUROENDOCRINOLOGY, 2018, 106 : 3 - 3
  • [27] Well-differentiated neuroendocrine tumors of the digestive tract: Focus on pancreatic neuroendocrine tumors
    Pellat, Anna
    Barat, Maxime
    Cottereau, Anne-Segolene
    Terris, Benoit
    Coriat, Romain
    BULLETIN DU CANCER, 2023, 110 (09) : 955 - 967
  • [28] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
    Panzuto, F.
    Rinzivillo, M.
    Spada, F.
    Antonuzzo, L.
    Ibrahim, T.
    Campana, D.
    Fazio, N.
    Delle Fave, G.
    NEUROENDOCRINOLOGY, 2016, 103 : 83 - 83
  • [29] Everolimus in Pancreatic Neuroendocrine Carcinomas G3
    Panzuto, Francesco
    Rinzivillo, Maria
    Spada, Francesca
    Antonuzzo, Lorenzo
    Ibrahim, Toni
    Campana, Davide
    Fazio, Nicola
    Delle Fave, Gianfranco
    PANCREAS, 2017, 46 (03) : 302 - 305
  • [30] First-line fluoropyrimidine and oxaliplatin chemotherapy in gastro-entero-pancreatic grade III well-differentiated neuroendocrine tumors (NET G3).
    Lamberti, Giuseppe
    Pusceddu, Sara
    Ibrahim, Toni
    Bongiovanni, Alberto
    Prinzi, Natalie
    Maggio, Ilaria
    Campana, Davide
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345